Acrivon director granted 20,275 stock options
Acrivon Therapeutics director Charles M. Baum received a grant of stock options for 20,275 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Acrivon Therapeutics director Charles M. Baum received a grant of stock options for 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036. All 20,275 options will vest immediately before Acrivon’s next annual stockholder meeting, contingent on his continuous service.
Insider Trade Summary
Grant/Award: 20,275 shares
Grant/Award
1 txn
Insider
BAUM CHARLES M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 20,275 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,275 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
Key Figures
Option grant size: 20,275 options
Exercise price: $1.52 per share
Underlying shares: 20,275 shares
+2 more
5 metrics
Option grant size
20,275 options
Stock Option (Right to Buy) grant on June 17, 2026
Exercise price
$1.52 per share
Conversion or exercise price of option grant
Underlying shares
20,275 shares
Underlying Acrivon common stock for the option grant
Post-transaction holdings
20,275 options
Total derivative securities following the grant
Option expiration
June 16, 2036
Expiration date of the stock options
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.5200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-16T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
continuous service financial
"subject to the Reporting Person's continuous service through the applicable vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Acrivon Therapeutics (ACRV) director Charles M. Baum report on this Form 4?
Director Charles M. Baum reported receiving a grant of stock options covering 20,275 shares of Acrivon Therapeutics common stock. The options were acquired at an exercise price of $1.52 per share and represent a derivative security rather than an immediate purchase of common shares.
What are the key terms of Charles M. Baum’s ACRV stock option grant?
The option grant covers 20,275 underlying shares of Acrivon Therapeutics common stock with an exercise price of $1.52 per share. The options expire on June 16, 2036, giving a long exercise window if vesting and other conditions are satisfied.
When do Charles M. Baum’s Acrivon Therapeutics options vest?
The options vest on the date immediately preceding Acrivon Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on Charles M. Baum’s continuous service with the company through that vesting date, according to the footnote in the Form 4 filing.
How many Acrivon Therapeutics derivative securities does Charles M. Baum hold after this transaction?
Following the transaction, Charles M. Baum holds 20,275 stock options directly. These options each relate to one share of Acrivon Therapeutics common stock as the underlying security, according to the reported total shares following the transaction on the Form 4.
Is this ACRV Form 4 transaction a market purchase or sale of stock?
This Form 4 reports a grant of stock options, not an open-market purchase or sale of common stock. The transaction is coded as an acquisition (A) of derivative securities with an exercise price of $1.52 per share rather than a cash transaction in the market.
What is the expiration date of Charles M. Baum’s ACRV stock options?
The reported stock options for 20,275 underlying Acrivon Therapeutics shares expire on June 16, 2036. After this expiration date, any unexercised portion of the option grant will lapse and no longer be exercisable under the terms disclosed in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates